Myovant Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Myovant Sciences's estimated annual revenue is currently $144.9M per year.
- Myovant Sciences received $86.2M in venture funding in July 2018.
- Myovant Sciences's estimated revenue per employee is $501,557
- Myovant Sciences's total funding is $200M.
- Myovant Sciences's current valuation is $1.4B. (January 2022)
Employee Data
- Myovant Sciences has 289 Employees.
- Myovant Sciences grew their employee count by -4% last year.
Myovant Sciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Director Sales and Marketing Operations | Reveal Email/Phone |
2 | Executive Director, Business Development & Licensing | Reveal Email/Phone |
3 | VP, Global Market Access and Health Economics / Outcomes Research | Reveal Email/Phone |
4 | VP Biostatistics | Reveal Email/Phone |
5 | VP Sales, Oncology | Reveal Email/Phone |
6 | VP Regulatory Affairs | Reveal Email/Phone |
7 | VP Commercial Supply Chain & Contract Manufacturing | Reveal Email/Phone |
8 | Head, Drug Safety and Pharmacovigilance | Reveal Email/Phone |
9 | Head, Policy and Public Affairs | Reveal Email/Phone |
10 | SVP - Medical Affairs | Reveal Email/Phone |
Myovant Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Myovant Sciences?
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders. Myovant's lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women's health and endocrine-related disorders. For more information, please visit the company's website at myovant.com.
keywords:N/A
$200M
Total Funding
289
Number of Employees
$144.9M
Revenue (est)
-4%
Employee Growth %
$1.4B
Valuation
N/A
Accelerator
Myovant Sciences News
The steep decline in Myovant Sciences share price is due to an FDA notice regarding relugolix label expansion for endometriosis.
Myovant Sciences is a healthcare company focused on redefining care through differentiated solutions in high unmet need areas within women's...
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative...
The recent performance of Myovant Sciences Ltd. (NYSE:MYOV) stock in the market spoke loud and clear to investors as MYOV saw more than ...
Former hedge fund partner Vivek Ramaswamy's collection of "vants" — including Brisbane-based, women's health-focused Myovant Sciences ...
Other Companies in Brisbane
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15M | 289 | 8% | N/A |
#2 | $87.6M | 295 | 5% | N/A |
#3 | $80.9M | 300 | 5% | N/A |
#4 | $35M | 300 | N/A | N/A |
#5 | $96.8M | 306 | 4% | N/A |
Myovant Sciences Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-10-17 | $140.0M | Undisclosed | NovaQuest Capital Management | Article |
| 2018-07-12 | $86.2M | Undisclosed | J.P. Morgan Securities LLC | Article |